nach oben

Journal of Gastroenterology

Erschienen in:

22.12.2015 | Review

Role of contrast-enhanced ultrasonography with Sonazoid for hepatocellular carcinoma: evidence from a 10-year experience

verfasst von: Hitoshi Maruyama, Tadashi Sekimoto, Osamu Yokosuka

Erschienen in: Journal of Gastroenterology | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

Hepatocellular carcinoma (HCC) represents primary liver cancer. Because the development of HCC limits the prognosis as well as the quality of life of the patients, its management should be properly conducted based on an accurate diagnosis. The liver is the major target organ of ultrasound (US), which is the simple, non-invasive, and real-time imaging method available worldwide. Microbubble-based contrast agents are safe and reliable and have become popular, which has resulted in the improvement of diagnostic performances of US due to the increased detectability of the peripheral blood flow. Sonazoid (GE Healthcare, Waukesha, WI, USA), a second-generation contrast agent, shows the unique property of accumulation in the liver and spleen. Contrast-enhanced US with Sonazoid is now one of the most frequently used modalities in the practical management of liver tumors, including the detection and characterization of the nodule, evaluation of the effects of non-surgical treatment, intraoperative support, and post-treatment surveillance. This article reviews the 10-year evidence for contrast-enhanced US with Sonazoid in the practical management of HCC.

Kudo M, Matsui O, Izumi N, Liver Cancer Study Group of Japan, et al. Surveillance and diagnostic algorithm for hepatocellular carcinoma proposed by the Liver Cancer Study Group of Japan: 2014 update. Oncology. 2014;87(Suppl 1):7–21.CrossRefPubMed

Jang HJ, Kim TK, Burns PN, et al. CEUS: an essential component in a multimodality approach to small nodules in patients at high-risk for hepatocellular carcinoma. Eur J Radiol. 2015;84:1623–35.CrossRefPubMed

Bouakaz A, de Jong N. WFUMB Safety Symposium on Echo-Contrast Agents: nature and types of ultrasound contrast agents. Ultrasound Med Biol. 2007;33:187–96.CrossRefPubMed

Numata K, Luo W, Morimoto M, et al. Contrast-enhanced ultrasound of hepatocellular carcinoma. World J Radiol. 2010;2:68–82.CrossRefPubMedPubMedCentral

Claudon M, Dietrich CF, Choi BI, et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver—update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound Med Biol. 2013;39:187–210.CrossRefPubMed

Sontum PC. Physicochemical characteristics of SonazoidTM, a new contrast agent for ultrasound imaging. Ultrasound Med Biol. 2008;34:824–33.CrossRefPubMed

Sasaki S, Iijima H, Moriyasu F, Hidehiko W. Definition of contrast enhancement phases of the liver using a perfluoro-based microbubble agent, perflubutane microbubbles. Ultrasound Med Biol. 2009;35:1819–27.CrossRef

Drugs in Japan forum. Drugs in Japan, ethical drugs 2011. Tokyo: Jiho; 2010.

Moriyasu F, Itoh K. Efficacy of perflubutane microbubble-enhanced ultrasound in the characterization and detection of focal liver lesions: phase 3 multicenter clinical trial. AJR Am J Roentgenol. 2009;193:86–95.CrossRefPubMed

10.

Shimada T, Maruyama H, Sekimoto T, et al. Heterogeneous staining in the liver parenchyma after the injection of perflubutane microbubble contrast agent. Ultrasound Med Biol. 2012;38:1317–23.CrossRefPubMed

11.

Inoue T, Kudo M, Hatanaka K, et al. Imaging of hepatocellular carcinoma: qualitative and quantitative analysis of post vascular phase contrast-enhanced ultrasonography with Sonazoid. Comparison with super paramagnetic iron oxide magnetic resonance images. Oncology. 2008;75(Suppl 1):48–54.CrossRefPubMed

12.

Goto E, Masuzaki R, Tateishi R, et al. Value of post-vascular phase (Kupffer imaging) by contrast-enhanced ultrasonography using Sonazoid in the detection of hepatocellular carcinoma. J Gastroenterol. 2012;47:477–85.CrossRefPubMed

13.

Hatanaka K, Chung H, Kudo M, et al. Usefulness of the post-vascular phase of contrast-enhanced ultrasonography with Sonazoid in the evaluation of gross types of hepatocellular carcinoma. Oncology. 2010;78(Suppl 1):53–9.CrossRefPubMed

14.

Tada T, Kumada T, Toyoda H, et al. Utility of contrast-enhanced ultrasound with perflubutane for diagnosing the macroscopic type of small nodular hepatocellular carcinomas. Eur Radiol. 2014;24:2157–66.CrossRefPubMed

15.

Hatanaka K, Minami Y, Kudo M, et al. The gross classification of hepatocellular carcinoma: usefulness of contrast-enhanced US. J Clin Ultrasound. 2014;42:1–8.CrossRefPubMed

16.

Mandai M, Koda M, Matono T, et al. Assessment of hepatocellular carcinoma by contrast-enhanced ultrasound with perfluorobutane microbubbles: comparison with dynamic CT. Br J Radiol. 2011;84:499–507.CrossRefPubMedPubMedCentral

17.

Numata K, Fukuda H, Miwa H, et al. Contrast-enhanced ultrasonography findings using a perflubutane-based contrast agent in patients with early hepatocellular carcinoma. Eur J Radiol. 2014;83:95–102.CrossRefPubMed

18.

Maruyama H, Takahashi M, Ishibashi H, et al. Contrast-enhanced ultrasound for characterisation of hepatic lesions appearing non-hypervascular on CT in chronic liver diseases. Br J Radiol. 2012;85:351–7.CrossRefPubMedPubMedCentral

19.

Kudo M, Hatanaka K, Inoue T, et al. Depiction of portal supply in early hepatocellular carcinoma and dysplastic nodule: value of pure arterial ultrasound imaging in hepatocellular carcinoma. Oncology. 2010;78(Suppl 1):60–7.CrossRefPubMed

20.

Kita R, Sakamoto A, Nagata Y, et al. Visualization of blood drainage area from hypervascular hepatocellular carcinoma on ultrasonographic images during hepatic arteriogram: comparison with depiction of drainage area on contrast-enhanced ultrasound. Hepatol Res. 2012;42:999–1007.CrossRefPubMed

21.

Sugimoto K, Shiraishi J, Moriyasu F, et al. Computer-aided diagnosis of focal liver lesions by use of physicians’ subjective classification of echogenic patterns in baseline and contrast-enhanced ultrasonography. Acad Radiol. 2009;16:401–11.CrossRefPubMed

22.

Numata K, Fukuda H, Nihonmatsu H, et al. Use of vessel patterns on contrast-enhanced ultrasonography using a perflubutane-based contrast agent for the differential diagnosis of regenerative nodules from early hepatocellular carcinoma or high-grade dysplastic nodules in patients with chronic liver disease. Abdom Imaging. 2015;40:2372–83.CrossRefPubMed

23.

Luo W, Numata K, Kondo M, et al. Sonazoid-enhanced ultrasonography for evaluation of the enhancement patterns of focal liver tumors in the late phase by intermittent imaging with a high mechanical index. J Ultrasound Med. 2009;28:439–48.PubMed

24.

Hatanaka K, Kudo M, Minami Y, et al. Sonazoid-enhanced ultrasonography for diagnosis of hepatic malignancies: comparison with contrast-enhanced CT. Oncology. 2008;75(Suppl 1):42–7.CrossRefPubMed

25.

Kan M, Hiraoka A, Uehara T, et al. Evaluation of contrast-enhanced ultrasonography using perfluorobutane (Sonazoid^®) in patients with small hepatocellular carcinoma: comparison with dynamic computed tomography. Oncol Lett. 2010;1:485–8.PubMedPubMedCentral

26.

Takahashi M, Maruyama H, Shimada T, et al. Characterization of hepatic lesions (≤30 mm) with liver-specific contrast agents: a comparison between ultrasound and magnetic resonance imaging. Eur J Radiol. 2013;82:75–84.CrossRefPubMed

27.

Mita K, Kim SR, Kudo M, et al. Diagnostic sensitivity of imaging modalities for hepatocellular carcinoma smaller than 2 cm. World J Gastroenterol. 2010;16:4187–92.CrossRefPubMedPubMedCentral

28.

Kawada N, Ohkawa K, Tanaka S, et al. Improved diagnosis of well-differentiated hepatocellular carcinoma with gadolinium ethoxybenzyl diethylene triamine pentaacetic acid-enhanced magnetic resonance imaging and Sonazoid contrast-enhanced ultrasonography. Hepatol Res. 2010;40:930–6.CrossRefPubMed

29.

Alaboudy A, Inoue T, Hatanaka K, et al. Usefulness of combination of imaging modalities in the diagnosis of hepatocellular carcinoma using Sonazoid^®-enhanced ultrasound, gadolinium diethylene-triamine-pentaacetic acid-enhanced magnetic resonance imaging, and contrast-enhanced computed tomography. Oncology. 2011;81(Suppl 1):66–72.CrossRefPubMed

30.

Ohama H, Imai Y, Nakashima O, et al. Images of Sonazoid-enhanced ultrasonography in multistep hepatocarcinogenesis: comparison with Gd-EOB-DTPA-enhanced MRI. J Gastroenterol. 2014;49:1081–93.CrossRefPubMed

31.

Kudo M. Multistep human hepatocarcinogenesis: correlation of imaging with pathology. J Gastroenterol. 2009;44(Suppl 19):112–8.CrossRefPubMed

32.

Suzuki K, Okuda Y, Ota M, et al. Diagnosis of hepatocellular carcinoma nodules in patients with chronic liver disease using contrast-enhanced sonography: usefulness of the combination of arterial- and Kupffer-phase enhancement patterns. J Ultrasound Med. 2015;34:423–33.CrossRefPubMed

33.

Tanaka H, Iijima H, Higashiura A, et al. New malignant grading system for hepatocellular carcinoma using the Sonazoid contrast agent for ultrasonography. J Gastroenterol. 2014;49:755–63.CrossRefPubMed

34.

Kondo T, Maruyama H, Kiyono S, et al. Intensity-based assessment of microbubble-enhanced ultrasonography: phase-related diagnostic ability for cellular differentiation of hepatocellular carcinoma. Ultrasound Med Biol. 2015;41:3079–87.CrossRefPubMed

35.

Maruyama H, Takahashi M, Ishibashi H, et al. Changes in tumor vascularity precede microbubble contrast accumulation deficit in the process of dedifferentiation of hepatocellular carcinoma. Eur J Radiol. 2010;75:e102–6.CrossRefPubMed

36.

Takahashi M, Maruyama H, Ishibashi H, et al. Contrast-enhanced ultrasound with perflubutane microbubble agent: evaluation of differentiation of hepatocellular carcinoma. AJR Am J Roentgenol. 2011;196:W123–31.CrossRefPubMed

37.

Sugimoto K, Moriyasu F, Saito K, et al. Comparison of Kupffer-phase Sonazoid-enhanced sonography and hepatobiliary-phase gadoxetic acid-enhanced magnetic resonance imaging of hepatocellular carcinoma and correlation with histologic grading. J Ultrasound Med. 2012;31:529–38.PubMed

38.

Kondo T, Maruyama H, Sekimoto T, et al. Natural history of postvascular-phase iso-enhanced lesions on the sonogram in chronic liver diseases. J Gastroenterol Hepatol. 2014;29:165–72.CrossRefPubMed

39.

Korenaga K, Korenaga M, Furukawa M, et al. Usefulness of Sonazoid contrast-enhanced ultrasonography for hepatocellular carcinoma: comparison with pathological diagnosis and super paramagnetic iron oxide magnetic resonance images. J Gastroenterol. 2009;44:733–41.CrossRefPubMed

40.

Maruyama H, Takahashi M, Sekimoto T, et al. Heterogeneity of microbubble accumulation: a novel approach to discriminate between well-differentiated hepatocellular carcinomas and regenerative nodules. Ultrasound Med Biol. 2012;38:383–8.CrossRefPubMed

41.

Choi BI, Lee JM, Kim TK, et al. Diagnosing borderline hepatic nodules in hepatocarcinogenesis: imaging performance. AJR Am J Roentgenol. 2015;205:10–21.CrossRefPubMed

42.

Kudo M, Hatanaka K, Kumada T, et al. Double-contrast ultrasound: a novel surveillance tool for hepatocellular carcinoma. Am J Gastroenterol. 2011;106:368–70.CrossRefPubMed

43.

Maruyama H, Takahashi M, Ishibashi H, et al. Ultrasound-guided treatments under low acoustic power contrast harmonic imaging for hepatocellular carcinomas undetected by B-mode ultrasonography. Liver Int. 2009;29:708–14.CrossRefPubMed

44.

Miyamoto N, Hiramatsu K, Tsuchiya K, et al. Contrast-enhanced sonography-guided radiofrequency ablation for the local recurrence of previously treated hepatocellular carcinoma undetected by B-mode sonography. J Clin Ultrasound. 2010;38:339–45.PubMed

45.

Numata K, Morimoto M, Ogura T, et al. Ablation therapy guided by contrast-enhanced sonography with Sonazoid for hepatocellular carcinoma lesions not detected by conventional sonography. J Ultrasound Med. 2008;27:395–406.PubMed

46.

Minami Y, Kudo M, Hatanaka K, et al. Radiofrequency ablation guided by contrast harmonic sonography using perfluorocarbon microbubbles (Sonazoid) for hepatic malignancies: an initial experience. Liver Int. 2010;30:759–64.CrossRefPubMed

47.

Kudo M. New sonographic techniques for the diagnosis and treatment of hepatocellular carcinoma. Hepatol Res. 2007;37(Suppl 2):S193–9.CrossRefPubMed

48.

Kudo M, Hatanaka K, Maekawa K. Newly developed novel ultrasound technique, defect reperfusion ultrasound imaging, using Sonazoid in the management of hepatocellular carcinoma. Oncology. 2010;78(Suppl 1):40–5.CrossRefPubMed

49.

Ikeda K, Osaki Y, Nakanishi H, et al. Recent progress in radiofrequency ablation therapy for hepatocellular carcinoma. Oncology. 2014;87(Suppl 1):73–7.CrossRefPubMed

50.

Meloni MF, Smolock A, Cantisani V, et al. Contrast enhanced ultrasound in the evaluation and percutaneous treatment of hepatic and renal tumors. Eur J Radiol. 2015;84:1666–74.CrossRefPubMed

51.

Hiraoka A, Ichiryu M, Tazuya N, et al. Clinical translation in the treatment of hepatocellular carcinoma following the introduction of contrast-enhanced ultrasonography with Sonazoid. Oncol Lett. 2010;1:57–61.PubMedPubMedCentral

52.

Masuzaki R, Shiina S, Tateishi R, et al. Utility of contrast-enhanced ultrasonography with Sonazoid in radiofrequency ablation for hepatocellular carcinoma. J Gastroenterol Hepatol. 2011;26:759–64.CrossRefPubMed

53.

Dohmen T, Kataoka E, Yamada I, et al. Efficacy of contrast-enhanced ultrasonography in radiofrequency ablation for hepatocellular carcinoma. Intern Med. 2012;51:1–7.CrossRefPubMed

54.

Kudo M. Diagnostic imaging of hepatocellular carcinoma: recent progress. Oncology. 2011;81(Suppl 1):73–85.CrossRefPubMed

55.

Inoue T, Kudo M, Hatanaka K, et al. Usefulness of contrast-enhanced ultrasonography to evaluate the post-treatment responses of radiofrequency ablation for hepatocellular carcinoma: comparison with dynamic CT. Oncology. 2013;84(Suppl 1):51–7.CrossRefPubMed

56.

Nishigaki Y, Hayashi H, Tomita E, et al. Usefulness of contrast-enhanced ultrasonography using Sonazoid for the assessment of therapeutic response to percutaneous radiofrequency ablation for hepatocellular carcinoma. Hepatol Res. 2015;45:432–40.CrossRefPubMed

57.

Inoue T, Minami Y, Chung H, et al. Radiofrequency ablation for hepatocellular carcinoma: assistant techniques for difficult cases. Oncology. 2010;78(Suppl 1):94–101.CrossRefPubMed

58.

Andreana L, Kudo M, Hatanaka K, et al. Contrast-enhanced ultrasound techniques for guiding and assessing response to locoregional treatments for hepatocellular carcinoma. Oncology. 2010;78(Suppl 1):68–77.CrossRefPubMed

59.

Takahashi M, Maruyama H, Shimada T, et al. Linear enhancement after radio-frequency ablation for hepatocellular carcinoma: Is it a sign of recurrence? Ultrasound Med Biol. 2012;38:1902–10.CrossRefPubMed

60.

Maruyama H, Takahashi M, Shimada T, et al. Pretreatment microbubble-induced enhancement in hepatocellular carcinoma predicts intrahepatic distant recurrence after radiofrequency ablation. AJR Am J Roentgenol. 2013;200:570–7.CrossRefPubMed

61.

Xia Y, Kudo M, Minami Y, et al. Response evaluation of transcatheter arterial chemoembolization in hepatocellular carcinomas: the usefulness of sonazoid-enhanced harmonic sonography. Oncology. 2008;75(Suppl 1):99–105.CrossRefPubMed

62.

Takizawa K, Numata K, Morimoto M, et al. Use of contrast-enhanced ultrasonography with a perflubutane-based contrast agent performed 1 day after transarterial chemoembolization for the early assessment of residual viable hepatocellular carcinoma. Eur J Radiol. 2013;82:1471–80.CrossRefPubMed

63.

Kudo M. The 2008 Okuda lecture: management of hepatocellular carcinoma: from surveillance to molecular targeted therapy. J Gastroenterol Hepatol. 2010;25:439–52.CrossRefPubMed

64.

Shiozawa K, Watanabe M, Kikuchi Y, et al. Evaluation of sorafenib for hepatocellular carcinoma by contrast-enhanced ultrasonography: a pilot study. World J Gastroenterol. 2012;18:5753–8.CrossRefPubMedPubMedCentral

65.

Sugimoto K, Moriyasu F, Saito K, et al. Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US. Liver Int. 2013;33:605–15.CrossRefPubMed

66.

Abo T, Nanashima A, Tobinaga S, et al. Usefulness of intraoperative diagnosis of hepatic tumors located at the liver surface and hepatic segmental visualization using indocyanine green-photodynamic eye imaging. Eur J Surg Oncol. 2015;41:257–64.CrossRefPubMed

67.

Uchiyama K, Ueno M, Ozawa S, et al. Combined intraoperative use of contrast-enhanced ultrasonography imaging using a Sonazoid and fluorescence navigation system with indocyanine green during anatomical hepatectomy. Langenbecks Arch Surg. 2011;396:1101–7.CrossRefPubMed

68.

Nanashima A, Tobinaga S, Abo T, et al. Usefulness of Sonazoid-ultrasonography during hepatectomy in patients with liver tumors: a preliminary study. J Surg Oncol. 2011;103:152–7.CrossRefPubMed

69.

Arita J, Takahashi M, Hata S, et al. Usefulness of contrast-enhanced intraoperative ultrasound using Sonazoid in patients with hepatocellular carcinoma. Ann Surg. 2011;254:992–9.CrossRefPubMed

70.

Mitsunori Y, Tanaka S, Nakamura N, et al. Contrast-enhanced intraoperative ultrasound for hepatocellular carcinoma: high sensitivity of diagnosis and therapeutic impact. J Hepatobiliary Pancreat Sci. 2013;20:234–42.CrossRefPubMed

71.

Arita J, Hasegawa K, Takahashi M, et al. Correlation between contrast-enhanced intraoperative ultrasound using Sonazoid and histologic grade of resected hepatocellular carcinoma. AJR Am J Roentgenol. 2011;196:1314–21.CrossRefPubMed

72.

Sato K, Tanaka S, Mitsunori Y, et al. Contrast-enhanced intraoperative ultrasonography for vascular imaging of hepatocellular carcinoma: clinical and biological significance. Hepatology. 2013;57:1436–47.CrossRefPubMed

73.

Luo W, Numata K, Morimoto M, et al. Three-dimensional contrast-enhanced sonography of vascular patterns of focal liver tumors: pilot study of visualization methods. AJR Am J Roentgenol. 2009;192:165–73.CrossRefPubMed

74.

Luo W, Numata K, Morimoto M, et al. Clinical utility of contrast-enhanced three-dimensional ultrasound imaging with Sonazoid: findings on hepatocellular carcinoma lesions. Eur J Radiol. 2009;72:425–31.CrossRefPubMed

75.

Numata K, Fukuda H, Ohto M, et al. Evaluation of the therapeutic efficacy of high-intensity focused ultrasound ablation of hepatocellular carcinoma by three-dimensional sonography with a perflubutane-based contrast agent. Eur J Radiol. 2010;75:e67–75.CrossRefPubMed

76.

Kunishi Y, Numata K, Morimoto M, et al. Efficacy of fusion imaging combining sonography and hepatobiliary phase MRI with Gd-EOB-DTPA to detect small hepatocellular carcinoma. AJR Am J Roentgenol. 2012;198:106–14.CrossRefPubMed

77.

Makino Y, Imai Y, Ohama H, et al. Ultrasonography fusion imaging system increases the chance of radiofrequency ablation for hepatocellular carcinoma with poor conspicuity on conventional ultrasonography. Oncology. 2013;84(Suppl 1):44–50.CrossRefPubMed

78.

Min JH, Lim HK, Lim S, et al. Radiofrequency ablation of very-early-stage hepatocellular carcinoma inconspicuous on fusion imaging with B-mode US: value of fusion imaging with contrast-enhanced US. Clin Mol Hepatol. 2014;20:61–70.CrossRefPubMedPubMedCentral

79.

Numata K, Fukuda H, Morimoto M, et al. Use of fusion imaging combining contrast-enhanced ultrasonography with a perflubutane-based contrast agent and contrast-enhanced computed tomography for the evaluation of percutaneous radiofrequency ablation of hypervascular hepatocellular carcinoma. Eur J Radiol. 2012;81:2746–53.CrossRefPubMed

80.

Shindoh J, Seyama Y, Umekita N. Three-dimensional staining of liver segments with an ultrasound contrast agent as an aid to anatomic liver resection. J Am Coll Surg. 2012;215:e5–10.CrossRefPubMed

81.

Bota S, Piscaglia F, Marinelli S, et al. Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma. Liver Cancer. 2012;1:190–200.CrossRefPubMedPubMedCentral

82.

Tanaka H, Iijima H, Nouso K, et al. Cost-effectiveness analysis on the surveillance for hepatocellular carcinoma in liver cirrhosis patients using contrast-enhanced ultrasonography. Hepatol Res. 2012;42:376–84.CrossRefPubMed

83.

Shiozawa K, Watanabe M, Takayama R, et al. Evaluation of local recurrence after treatment for hepatocellular carcinoma by contrast-enhanced ultrasonography using Sonazoid: comparison with dynamic computed tomography. J Clin Ultrasound. 2010;38:182–9.PubMed

Titel: Role of contrast-enhanced ultrasonography with Sonazoid for hepatocellular carcinoma: evidence from a 10-year experience
verfasst von: Hitoshi Maruyama
Tadashi Sekimoto
Osamu Yokosuka
Publikationsdatum: 22.12.2015
Verlag: Springer Japan
Erschienen in: Journal of Gastroenterology / Ausgabe 5/2016
Print ISSN: 0944-1174
Elektronische ISSN: 1435-5922
DOI: https://doi.org/10.1007/s00535-015-1151-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Role of contrast-enhanced ultrasonography with Sonazoid for hepatocellular carcinoma: evidence from a 10-year experience

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2016

Is serum HER2 ECD a predictive biomarker for response to trastuzumab in advanced gastric cancer?

Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features

Fecal calprotectin: its scope and utility in the management of inflammatory bowel disease

Host–virus interactions in hepatitis B and hepatitis C infection

Hepatitis B surface antigen seroclearance during nucleoside analogue therapy: surface antigen kinetics, outcomes, and durability

Factors affecting recurrence and prognosis after R0 resection for colorectal cancer with peritoneal metastasis

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin